Rhabdomyolysis Due to Micronized Fenofibrate

Abstract

Fenofibrate, a fibric acid derivative, is frequently used to treat diabetic dyslipidemia and hypertriglyceridemia alone or in combination with statins. Rhabdomyolysis is a syndrome that results from striated muscle necrosis and release of its contents into the systemic circulation and extracellular fluid. Fenofibrate-induced rhabdomyolysis is a rare clinical condition if there is not a predisposing factor such as diabetes mellitus, hypothyroidism, and renal insufficiency. In this study, we present a case of a patient who developed rhabdomyolysis after micronized fenofibrate use without known predisposing factor.